80719-70-6

Upstream product

• 3756-30-7 1-iodo-2-methyl-2-propene 
• 77877-20-4 (4R,5S)-4-methyl-5-phenyl-3-propionyloxazolidin-2-one 
• 1458-98-6 2-methyl-3-bromo-1-propene 
• 492-39-7 (1S,2S)-2-amino-1-phenylpropanol 
• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 

Downstream Products

• 130808-32-1 (2R,4S,5S,6S)-(+)-7-t-butyldiphenylsilyloxy-5-ethyl-2,4-dimethylheptane-1,5-diol 
• 130514-50-0 (2'R,3'S,4R,4'S,5S,6'R)-(+)-3-(2'-ethyl-3',7'-dihydroxy-4',6'-dimethyl-1'-oxoheptyl)-4-methyl-5-phenyloxazolidin-2-one 
• 107691-85-0 (2'R,3'S,4R,4'S,5S)-(-)-3-(2'-ethyl-4',6'-dimethyl-1'-oxo-3'-trimethylsilyloxyhept-6'-enyl)-4-methyl-5-phenyloxazolidin-2-one 
• 130514-54-4 (1'S,3R,5S,6S)-(+)-6-<1'-(t-butyldiphenylsilyloxymethyl)propyl>-3,5-dimethyltetrahydropyran-2-one 
• 107691-86-1 (2'R,3'S,4R,4'S,5S,6'R)-(-)-3-(2'-ethyl-7'-hydroxy-4',6'-dimethyl-1'-oxo-3'-trimethylsilyloxyheptyl)-4-methyl-5-phenyloxazolidin-2-one 
• 130514-51-1 (4R,5S)-3-[(R)-2-((2S,3S,5R)-6-Hydroxy-3,5-dimethyl-tetrahydro-pyran-2-yl)-butyryl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 130514-52-2 (2'R,2''S,3''S,4R,5S,5''R)-(+)-<2'-(3'',5''-dimethyl-6''-oxotetrahydropyran-2''-yl)-1'-oxobutyl>-4-methyl-5-phenyloxazolidin-2-one 
• 107691-87-2 (2'R,3'S,4R,4'S,5S,6'R)-(-)-3-(7'-t-butyldimethylsilyloxy-2'-ethyl-4',6'-dimethyl-1'-oxo-3'-trimethylsilyloxyheptyl)-4-methyl-5-phenyloxazolidin-2-one 
• 130514-53-3 C₃₆H₆₄O₃Si₃ 
• 107691-84-9 (4R,5S)-3-((2S,3S,4S)-2-Ethyl-3-hydroxy-4,6-dimethyl-hept-6-enoyl)-4-methyl-5-phenyl-oxazolidin-2-one 
• 107691-84-9 (2'R,3'S,4R,4'S,5S)-(+)-3-(2'-ethyl-3'-hydroxy-4',6'-dimethyl-1'-oxohept-6'-enyl)-4-methyl-5-phenyloxazolidin-2-one 
• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 
• 82507-47-9 (S)-(-)-2,4-dimethylpent-4-en-1-ol 
• 69056-12-8 (+)-Prelog-Djerassi lactonic acid 

Relevant academic research and scientific papers

Thermal proteome profiling efficiently identifies ribosome destabilizing oxazolidinones

Identifying the targets of bioactive small molecules is a challenging endeavor for which no general solution currently exists. Classical affinity purification experiments suffer from the need to functionalise a bioactive compound and link it to a solid support, which may interfere with target binding. A modern mass spectrometry-based proteomics technique that has partially circumvented this problem is thermal proteome profiling (TPP), which determines the effect of an unmodified small molecule on the thermal stability of the whole proteome simultaneously. Here, we use TPP to identify the mode-of-action of a newly-discovered autophagy inhibitor based on oxazolidinones often employed as chiral auxiliaries. Surprisingly, a significant portion of all ribosomal proteins were found to be destabilized by the inhibitor, highlighting the utility of this technology for determining a challenging mode-of-action.

Regulation of cholesterol homeostasis

The invention provides novel compounds of Formulas (I)-(IV), as described herein. Also provided are compositions of these compounds, method of making the compounds, and methods of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal lipid storage disorders such as Niemann-Pick Disease type C.

Stereocontrolled Synthesis of a Key Lactone Intermediate Required for the Synthesis of Salinomycin

The stereocontrolled synthesis of lactone (1b), a key intermediate required for the synthesis of the polyether antibiotic salinomycin, is described.

Stereoselective Reactions of Chiral Enolates. Application to the Synthesis of (+)-Prelog-Djerassi Lactonic Acid

The application of chiral metal enolates 3 and 4 have been employed in an efficient synthesis of (+)-Prelog-Djerassi lactone (1).